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S U M M A R Y
The best treatment for Tropheryma whipplei infections is controversial. We report a patient who suffered
from T. whipplei aortic native valve endocarditis that relapsed despite surgery and four weeks of
intravenous ceftriaxone followed by several months of oral trimethoprim/sulfamethoxazole. Cure was
achieved after replacement of the prosthesis with a homograft and 18 months of oral doxycycline-
hydroxychloroquine. We discuss the need for a change in treatment guidelines for T. whipplei infections.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Case Description
A 60 year old man with Child B cirrhosis secondary to chronic
alcohol abuse presented to our hospital with cardiac insufﬁciency.
Transthoracic and transesophageal echocardiography revealed
severe leaking of the aortic valve with a large vegetation (>1 cm).
The patient had lost weight during the last six months and was
asthenic, but did not complain of fever or arthralgia. White blood
cell count and C-reactive protein were normal. The aortic valve was
replaced by a Trifecta pericardial aortic bioprosthesis (St. Jude
Medical, Minnetonka, MN, USA) along with administration of
intravenous (iv) ceftriaxone, vancomycin and gentamycin.
Blood cultures performed before valvular replacement
remained negative after three weeks of incubation. Brucella,
Coxiella, Bartonella, Mycoplasma and Legionella serologic tests were* Corresponding author. Service of Infectious Diseases - University Hospitals
Geneva - 4, Rue Gabrielle-Perret-Gentil - CH-1211 Geneva 14 – Switzerland.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).negative. Gram staining of the explanted native aortic valve was
negative, but acridine orange staining revealed small rods
(Figure 1). The diagnosis of Tropheryma whipplei aortic endocarditis
was established by positive 16S rDNA broad range PCR performed
on valvular tissue. Speciﬁc T. whipplei immunohistochemistry was
retrospectively positive (Figure 2). Vancomycin and gentamycin
were discontinued and ceftriaxone was continued for one month,
followed by oral double-strength trimethoprim/sulfamethoxazole
(TMP-SMX) three times daily.
Five weeks after valvular replacement, while still receiving
TMP-SMX, the patient was admitted again with symptomatic
pericardial effusion. Transcutaneous drainage was followed by
clinical relapse with hemodynamic instability and fever. A
mediastinal collection was removed surgically, and a pericar-
dio-pleural fenestration of the pericardial membrane was
performed. All blood and mediastinal ﬂuid cultures were positive
for Enterococcus faecalis, suggesting prosthetic valve E. faecalis
endocarditis and mediastinitis. The bacterium was highly resis-
tant to gentamycin, but susceptible to penicillin. Conservative
treatment was attempted with iv amoxicillin two grams six times
daily and iv ceftriaxone two grams twice daily for eight weeks asciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Acridine orange staining revealing small rods in the valvular tissue.
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double strength TMP-SMX, which had been used since the ﬁrst
hospitalization. One month later, the patient was admitted again
with hematemesis. A gastroscopy revealed gastric hypertension
due to cirrhosis and mycotic esophagitis, without signs of
intestinal Whipple’s disease. Two weeks after admission, while
still taking TMP-SMX, the patient developed dyspnea with
peripheral edema and weight gain. A transesophageal echocardi-
ography showed partial de-insertion of the aortic prosthetic valve
associated with pseudo-aneurysm and vegetation on the posteri-
or aortic ring. Blood cultures as well as speciﬁc real-time PCR for T.
whipplei on peripheral blood were negative. The St-Jude bio-
prosthesis was replaced by a homograft, and TMP-SMX was
replaced with iv amoxicillin-ceftriaxone and oral doxycycline.
Direct examination, cultures and 16S broad-range PCR of the
explanted bioprosthesis remained negative. The operative mate-
rial (explanted valve and cardiac tissue) was sent to a reference
center in Marseille, France. The speciﬁc PCR for E. faecalis was
negative, but T. whipplei DNA could be recovered from para-
valvular tissue 5 months after the initial diagnosis, conﬁrming
relapsing Whipple’s endocarditis. The folP sequence was obtained
but did not show mutations associated with resistance to TMP-
SMX. Amoxicillin and ceftriaxone were discontinued, and hydro-
xychloroquine by mouth was added to doxycycline during
rehabilitation. The patient was treated for 18 months after the
last aortic replacement surgery without relapse ﬁve months after
the end of treatment.Figure 2. Immunohistochemical staining with polyclonal rabbit anti - T. whipplei
antibody and Mayer’s hemalum counterstain shows T. whipplei in the cardiac valve.2. Discussion
Tropheryma whipplei is a rare cause of endocarditis and was ﬁrst
reported in 1997 as an agent of blood culture-negative endocardi-
tis.2 The incidence of T. whipplei among blood culture-negative
agents ranges from 2,6 to 6.3% in France and Germany.3,4Whipple’s
endocarditis is mostly seen in men (>80%)5. It has been linked with
genetic predisposition suggested by the association with HLA B27
and HLA DRB*13 et DQB1*06.6 This association was not found in
our patient. His immunity was, however, compromised by alcohol
abuse and cirrhosis.
The diagnosis of T. whipplei endocarditis remains challenging
because clinical signs of infection are subtle or absent and
microbiological identiﬁcation is difﬁcult.7 The diagnosis frequently
relies on 16S rRNA ampliﬁcation and sequencing (or speciﬁc
immunohistochemistry) on explanted cardiac valve tissue.5,8, but
not on blood, where it performs poorly.3 Our initial diagnosis,
performed using 16S rDNA broad range PCR, was conﬁrmed by
speciﬁc PCR as well as immunohistochemistry.9,10 The relapse was
diagnosed by speciﬁc PCR performed on paravalvular tissue in a
reference center.10 This case highlights the higher sensitivity of
speciﬁc T. whipplei PCR than 16S rRNA ampliﬁcation and
sequencing as previously reported.10
The management of patients with T. whipplei infections
remains difﬁcult, and the use of TMP-SMX is controversial in
classic Whipple’s disease, characterized by a histological small-
bowel involvement.11–13 This drug was suggested empirically
for a prolonged suppressive treatment in classic Whipple’s
disease, after an initial therapy with either penicillin or
ceftriaxone, in order to reach high concentrations in CSF, which
are crucial in case of CNS involvement.14 Since then, the
cultivation of the causative intracellular bacteria allowed
building in vitro knowledge regarding antibiotic susceptibility.15
Genomic analysis and biological tests suggest that trimethoprim
is not active against T. whipplei, because its target is lacking, and
acquired resistance to sulfamethoxazole has been commonly
reported.5 To date, 34 cases of relapse have been reported after
treatment of classic Whipple’s disease with TMP-SMX.13,16,17
Among them, two cases of endocarditis in relapse of classic
Whipple’s disease have been published.16 Tetracyclines were
abandoned long ago due to a high failure rate, especially when
there was CNS involvement. Quinolones, usually active against
intra-cellular pathogens, are not a good option in Whipple’s
disease because of frequent mutation of the gyrA and parC
genes.18 The combination of doxycycline with hydroxychlor-
oquine has proven to be the only bactericidal treatment in
vitro.5 T. whipplei survives inside the phagosome by inhibiting
phago-lysosome fusion. It requires the acidic environment of the
vacuole to survive. Hydroxychloroquine favors the killing of
T. whipplei by augmenting the pH inside the phagosome.5,19
Clinicians should be aware of the side effects of long
antimicrobial therapy, such as alteration of the microbiota
accompanied by weight gain with doxycycline20, and the risk of
irreversible retinopathy with hydroxychloroquine21.
Classically, the outcome of patients suffering localized
T. whipplei endocarditis is better than those with classic Whipple’s
disease. The present case clearly documents for the ﬁrst time a
relapse of T. whipplei endocarditis treated by TMP-SMX. The
latter may not be adequate to treat T. whipplei infections, as
predicted by the in vitro tests and highlighted by the treatment
failure described in this case and many others.19 Treatment
guidelines should probably be modiﬁed accordingly.
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